Literature DB >> 24048366

Influence of body mass index on survival in veterans with multiple myeloma.

Tracey S Beason1, Su-Hsin Chang, Kristen M Sanfilippo, Suhong Luo, Graham A Colditz, Ravi Vij, Michael H Tomasson, John F Dipersio, Keith Stockerl-Goldstein, Arun Ganti, Tanya Wildes, Kenneth R Carson.   

Abstract

PURPOSE: We investigated the association between body mass index (BMI) at the time of multiple myeloma (MM) diagnosis and overall survival in a cohort of patients within the Veterans Health Administration system. We also evaluated the association between weight loss in the year prior to diagnosis and survival. PATIENTS AND METHODS: Prospective analysis was performed on a retrospectively assembled cohort of 2,968 U.S. veterans diagnosed and treated for MM between September 1, 1999, and September 30, 2009, with follow-up information through October 22, 2011. Cox modeling controlling for patient- and disease-related prognostic variables was used to analyze the data.
RESULTS: Underweight patients (BMI <18.5 kg/m2) had increased mortality, whereas patients who were overweight (BMI 25-29.9 kg/m2) and obese (BMI ≥30 kg/m2) had lower mortality compared with healthy-weight patients (BMI 18.5-24.9 kg/m2). Weight loss ≥10% of baseline in the year before diagnosis was also associated with increased mortality and made the association between increased BMI and survival nonsignificant.
CONCLUSION: Disease-related weight loss may be an important and heretofore unknown indicator of poor prognosis in MM. Assessment of weight loss prior to MM diagnosis should become a standard component of the clinical history in patients with newly diagnosed MM. Further research may identify relationships between disease-related weight loss and currently used prognostic factors in MM, further defining the role of this clinical factor in prognostic stratification.

Entities:  

Keywords:  Body mass index; Mortality; Multiple myeloma; Obesity; Overweight; Survival

Mesh:

Year:  2013        PMID: 24048366      PMCID: PMC3805147          DOI: 10.1634/theoncologist.2013-0015

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  32 in total

1.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

2.  Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols.

Authors:  Massimo Breccia; Luca Mazzarella; Vincenzo Bagnardi; Davide Disalvatore; Giuseppina Loglisci; Giuseppe Cimino; Anna Maria Testi; Giuseppe Avvisati; Maria Concetta Petti; Clara Minotti; Roberto Latagliata; Robin Foà; Pier Giuseppe Pelicci; Francesco Lo-Coco
Journal:  Blood       Date:  2011-11-02       Impact factor: 22.113

3.  C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.

Authors:  R Bataille; M Boccadoro; B Klein; B Durie; A Pileri
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

4.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.

Authors:  Andrea K Ng; M Patricia Bernardo; Edie Weller; Kendall H Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Jonathan Friedberg; George P Canellos; Peter M Mauch
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.

Authors:  C Cahlin; A Körner; H Axelsson; W Wang; K Lundholm; E Svanberg
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

7.  Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer.

Authors:  Brian C-H Chiu; Susan M Gapstur; Philip Greenland; Renwei Wang; Alan Dyer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12       Impact factor: 4.254

8.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

Review 9.  Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma.

Authors:  Marshall A Lichtman
Journal:  Oncologist       Date:  2010-10-07

10.  Accuracy and completeness of mortality data in the Department of Veterans Affairs.

Authors:  Min-Woong Sohn; Noreen Arnold; Charles Maynard; Denise M Hynes
Journal:  Popul Health Metr       Date:  2006-04-10
View more
  18 in total

1.  Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.

Authors:  Su-Hsin Chang; Suhong Luo; Theodore S Thomas; Katiuscia K O'Brian; Graham A Colditz; Nils P Carlsson; Kenneth R Carson
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

2.  Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.

Authors:  Su-Hsin Chang; Suhong Luo; Katiuscia K O'Brian; Theodore S Thomas; Graham A Colditz; Nils P Carlsson; Kenneth R Carson
Journal:  Lancet Haematol       Date:  2015-01       Impact factor: 18.959

3.  Diet-induced obesity promotes a myeloma-like condition in vivo.

Authors:  S T Lwin; S W Z Olechnowicz; J A Fowler; C M Edwards
Journal:  Leukemia       Date:  2014-10-07       Impact factor: 11.528

Review 4.  Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials.

Authors:  Heather Greenlee; Joseph M Unger; Michael LeBlanc; Scott Ramsey; Dawn L Hershman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-12-16       Impact factor: 4.254

Review 5.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

6.  Multiple Myeloma Mortality in Relation to Obesity Among African Americans.

Authors:  Jennifer S Sonderman; Traci N Bethea; Cari M Kitahara; Alpa V Patel; Chinonye Harvey; Synnøve F Knutsen; Yikyung Park; Song-Yi Park; Gary E Fraser; Lauren R Teras; Mark P Purdue; Rachael Z Stolzenberg-Solomon; Elizabeth M Gillanders; Julie R Palmer; Laurence N Kolonel; William J Blot
Journal:  J Natl Cancer Inst       Date:  2016-05-04       Impact factor: 13.506

Review 7.  The skinny on obesity and plasma cell myeloma: a review of the literature.

Authors:  K R Carson; M L Bates; M H Tomasson
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

8.  Prediagnosis dietary pattern and survival in patients with multiple myeloma.

Authors:  Dong Hoon Lee; Teresa T Fung; Fred K Tabung; Catherine R Marinac; Elizabeth E Devore; Bernard A Rosner; Irene M Ghobrial; Graham A Colditz; Edward L Giovannucci; Brenda M Birmann
Journal:  Int J Cancer       Date:  2020-02-28       Impact factor: 7.396

9.  Reflections on Cancer in the Bone Marrow: Adverse Roles of Adipocytes.

Authors:  Carolyne Falank; Heather Fairfield; Michaela R Reagan
Journal:  Curr Mol Biol Rep       Date:  2017-10-19

10.  Sclerostin-Neutralizing Antibody Treatment Rescues Negative Effects of Rosiglitazone on Mouse Bone Parameters.

Authors:  Mariah Farrell; Heather Fairfield; Samantha Costa; Anastasia D'Amico; Carolyne Falank; Daniel J Brooks; Michaela R Reagan
Journal:  J Bone Miner Res       Date:  2020-09-23       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.